Global Laparoscopic Robotic Assisted Prostatectomy Market 2026 – 2035

The size of the market in terms of USD of the global laparoscopic robotic assisted prostatectomy is estimated at USD 4.67 billion in the year 2026 and projected to reach USD 11.24 billion in the year 2035 and is expected to gain at an average of 9.2% per annum between the year 2026 and 2035.

The increasing worldwide rates of the second most commonly diagnosed cancer in men prostate cancer, the proven clinical superiority of robotic assisted prostatectomy over open and conventional laparoscopic surgery, the increasing global dissemination of robotic surgical platform technology out of academic medical centers into community hospitals, the gradual increase in competitive rivalry of robotic surgery systems as new systems challenge the historical Intuitive Surgical market share and stimulate price rivalry, the increasing use of nerve-sparing surgery procedures through the accuracy and magnification benefits of robotic platforms all represent strong market growth prospects throughout the forecast period.

Market Highlight

• North America- NAP had a market share of 46% in the laparoscopic robotic assisted prostatectomy market in 2025.

• Asia Pacific will have the highest CAGR of 13.4% within the period of 2026-2035.

• By product type, the robotic surgical systems segment received a market share of about 52% in 2025.

• By product type, the laparoscopic instruments and accessories segment has the highest CAGR (10.8%) in the period between 2026 and 2035.

• By the type of procedure, the highest market share of 67% was attributed to the radical prostatectomy segment in 2025 and the nerve-sparing prostatectomy segment is projected to have the highest CAGR of 11.6% in the forecasted period between 2026 and 2035.

• By end-user, the hospitals segment will have the largest market share of 74% in 2025, and the ambulatory surgical centers will have the highest CAGR of 14.2% between 2026 and 2035.

• Application wise, in 2025, the segment with the largest market share of 88% was the prostate cancer segment.

Significant Growth Factors

The Laparoscopic Robotic Assisted Prostatectomy Market Trends present significant growth opportunities due to several factors:

• Rising Global Prostate Cancer Incidence and Growing Surgical Treatment Utilization:

The underlying epidemiological force of the laparoscopic robotic assisted prostatectomy market is the rising case of prostate cancer on the globe, at least in the treatment of clinically localized and locally advanced prostate cancer, which is increasingly undertaken by robotic assisted means because of the aging populations of male populations and rising rates of prostate cancer incidence in the various populations previously of low incidence in prostate cancer, such as Asia, Africa, and Latin America.

The International Agency of Research on Cancer (IARC), a specialized agency of the World Health Organization database (GLOBOCAN 2022) has indicated a significant and increasing disease burden through prostate cancer which is the second most common cancer diagnosis in men with about 1.47 million new cases each year and the fifth leading cause of cancer death in men with about 397,000 deaths per year, which provides the surgical volume on which the robotic prostatectomy market was founded. In the United States, approximately 299,010 new prostate cancer cases and approximately 35,250 prostate cancer deaths were estimated in the year 2024 and the United States alone has the highest number of absolute prostate cancer cases of the individual countries of the world.

The incremental use of multiparametric MRI in detecting and staging prostate cancer, which allows more accurate detection of clinically relevant prostate cancer amenable to curative surgical therapy and optimal localization of tumor extent to drive nerve-sparing surgical planning, is helping to increase the volume of surgical treatment by the detection of surgically treatable disease in patients who would have previously been treated using active surveillance or radiation based on less accurate risk stratification. The impact of European population-based PSA screening programs on Sweden and Finland (and, in the U.S., new guidelines of the U.S. Preventive Services Task Force that suggest that each individual man should be allowed to make his own decision on PSA screening at ages 55–69) are also consequently affecting the rates of detection of prostate cancer at newer favorable stages to which the application of nerve-sparing surgical procedures could offer optimal functional outcomes. The aging of the worldwide male population (UN has estimated that the population of men over 60 years of age will be around 580 million in 2020 compared to 1.1 billion in 2050) will continue to increase prostate cancer incidence due to the high age dependency of the disease, most prostate cancers are diagnosed in men over 65 years old.

• Clinical Evidence Demonstrating Robotic Assisted Prostatectomy Superiority Over Open and Conventional Laparoscopic Approaches:

The growing body of comparative clinical data, including prospective cohort studies, systematic reviews, meta-analyses, and more recently randomized controlled trials, showing that robotic assisted laparoscopic prostatectomy (RALP) has better or equal oncological results to open radical retropubic prostatectomy (ORP) and has brought about clinically meaningful changes in perioperative outcomes such as blood loss, the need to take transfusion, length of stay in hospitals, the length of catheterization, and the level of pain after surgery, and functional An analysis of comparative outcomes of over 400,000 radical prostatectomies (a systematic review and meta-analysis in European Urology, among the most impactful journals in the field) revealed that RALP was linked with significantly reduced intraoperative blood loss (weighted mean difference of about 400 mL as compared to ORP), reduced transfusion, reduced length of stay (usually 1–2 days versus 3–6 days compared to ORP), and quicker recovery to urinary continence than open surgery and reached the same.

The nerve-sparing benefit of RALP, which came with the three-dimensional high-definition magnification of the da Vinci surgery system and equivalent robotic systems, allowing the visualization of the neurovascular bundles surrounding the prostate at extremes of detail that were not possible under open or conventional laparoscopic surgery, has been shown in published clinical series to enhance the preservation of erectile functions when compared to open nerve-sparing prostatectomy, a clinical outcome of paramount importance to patients diagnosed mostly in the 60 75 year age range and in whom the American Urological Association (AUA) and European Association of Urology (EAU) guidelines, the clinical practice standards of those regions in their respective geographic regions, both recognize robotic-assisted laparoscopic prostatectomy as a proven surgical technique in the localised treatment of prostate cancer, and the EAU guidelines add that robotic surgery has since become the predominant mode in centers with high volumes and training. Patient preferences reflecting the functional recovery profile attributed to robotic prostatectomy, shorter convalescence, reduced postoperative pain, and rapid readmission to everyday activities have been reported in patient-reported outcomes studies that include health-related quality of life scales based on validated measures such as the Expanded Prostate Cancer Index Composite (EPIC), and the appeal of shorter convalescence, lower postoperative pain, and quicker return to daily activities is more highly expressed among the comparatively youthful and energetic prostate cancer patient population who are working and leading active lifestyles during diagnosis.

What are the Major Advances Changing the Laparoscopic Robotic Assisted Prostatectomy Market Today?

• Competitive Robotic Surgery Platform Landscape Transforming Market Dynamics:

The move into the market by new robotic surgical system producers who are challenging the historical near-monopoly of Intuitive Surgical in the field of robotic assisted surgery, the sector that has been the market structure of the robotic prostatectomy business since the FDA approval of the da Vinci Surgical System in 2000, is fundamentally reorganizing the competitive dynamics of the laparoscopic robotic assisted prostatectomy business environment.

The da Vinci Surgical System, which made up the vast majority of worldwide robotic prostatectomies and cost USD 1.5-USD 2.5 million per platform based on the configuration, is sold by Intuitive Surgical, which charges USD 100,000-USD 300,000+ per annum per platform in the form of annual service and instrument maintenance, making the total cost of ownership extremely high and thus historically restricted the system to highly capitalized academic medical departments and large health system hospitals. Competitive procurement conditions are also being established by the market entry of rival robotic surgery platforms into the market, such as the Hugo RAS (Robotic Assisted Surgery) System of Medtronic, the Ottava system (under development) of Johnson and Johnson, the Versius System of CMR Surgical, and the avatera system of Avatera Medical, all of which give hospitals and health systems an opportunity to negotiate considerably better pricing conditions with the various competitor vendors. The Versius System introduced by CMR Surgical is targeted with a lower capital cost and smaller physical footprint than the da Vinci and market segments such as community hospitals and newer market healthcare systems where the entire da Vinci price point is an impediment to adoption.

The Hugo RAS System Intuitive Surgical has the greatest commercial significance as a competitor because of the scale of its commercial operations internationally, its established hospital connections in urology and other surgical specialties, and its financial capacity to invest in platform development and commercial growth. Medtronic, the Hugo RAS System, has secured CE Mark approval in Europe and regulatory approval in various overseas markets as of 2024, and the U.S. FDA clearance application is underway, which means its global commercial infrastructure, established connections, and financial wherewithal to invest in the development of its The heightened level of competitive intensity is already evident in the market pricing dynamics where the da Vinci system of Intuitive Surgical is reported to be experiencing greater pressure in the price negotiation by the key hospital system customers who are cognizant of the alternatives to robotic prostatectomy, as well as the cost per procedure of instruments; where previously the instrument cost per procedure was a significant portion of the total cost of robotic prostatectomy, and now, it is subject to the pressure of competition as well as new instrument reuse policies at the largest institutions.

• Single-Port Robotic Prostatectomy and Next-Generation Platform Capabilities:

One of the most technically relevant technical changes in robotic prostatectomy technique is the commercial introduction and subsequent growing use of single-port (SP) robotic prostatectomy, whereby all robotic instruments are inserted through a single skin incision and trocar instead of the traditional four or five port multiport access, which has minimally invasive potential benefits in cosmesis, postoperative pain, and recovery to carefully selected patients and allows the creation of new surgical methods such as the transvesical or transperineal robotic prostatectomy access pathways that may result in specific benefits in certain cases.

The da Vinci SP (Single Port) system of Intuitive Surgical, which is FDA approved to do urologic procedures since 2018 and is increasingly being used in high-volume robotic prostatectomy centers in North America and Europe, has a 2.5 cm skin opening that allows single-incision robotic prostatectomy with an accepted clinical history of equivalent oncological results published in multiple reports by institutions such as Johns Hopkins University School of Medicine and the University of Southern California Intuitive Surgical, Inc. Intuitive Surgical, Inc. and probably a higher rate of functional recovery than regular multiport robotic prostatectomy in selective patients. Opioid minimization has also been documented by published comparative studies of SP and multiport robotic prostatectomy with significant decreases in the postoperative opioid requirements - another important finding in the present opioid-minimization setting of the U.S. surgical practice - and reductions in the interval to resume daily activity in SP cohorts, which accounts for the increasing clinical interest in SP methods at centers with suitable training and patient-selection procedures.

The creation of next-generation robotic platform features such as haptic feedback systems, which can give surgeons the sensation of touching the tissue during robotic surgery and which cannot be provided by current clinical robotic systems, incorporation of fluorescence imaging systems that can provide real-time intraoperative visualization of the neurovascular bundles and lymphatic structures, and AI-based surgical guidance that can give the real-time identification of anatomy structures during robotic dissection are the directions of technology development that will shape competitive differentiation in the market of robotic surgery platform vendors

• Artificial Intelligence and Machine Learning Integration in Robotic Prostatectomy:

Current research on the integration of artificial intelligence and machine learning technologies into robotic surgical systems and perioperative management systems to enhance prostatectomy is transitioning out of research laboratory demonstrations and early clinical application, with applications in intraoperative anatomical localization, surgical phase detection, prognosticating the outcome modeling, and surgical training evaluation that collectively could help to enhance surgical performance consistency, lesson the learning curve on robotic prostatectomy skills acquisition, and individually customize patient-level counseling on AI-based intraoperative anatomical recognition systems based on deep convolutional neural networks trained on thousands of annotated surgical video videos are being developed to give real-time warnings of critical anatomical structures during robotic prostatectomy such as the neurovascular bundles, external urinary sphincter, and ureteral orifices, and may help to avoid the risk of accidental damage to continence-critical and erectile function-preserving structures during a complex dissection.

The surgical phase recognition feature, where AI systems trained on the video archives of robotic prostatectomies identify the currently performed step of the procedure and offer contextually relevant advice, alerts, or recommendations regarding the usage of surgical equipment, is currently being studied at several academic medical centers, with early publications showing that phase recognition accuracy is acceptable in all three standardized robotic prostatectomy surgical procedures. Predictive outcome modeling - Results of a study published in the Journal of Radiation Therapy finding that machine learning algorithms incorporating preoperative patient factors such as age, BMI, preoperative potency status, prostate volume, PSA level, and clinical stage coupled with intraoperative variables detected by robotic system telemetry would give rise to predictive outcomes of postoperative continence and erectile function recovery patterns are being developed at academic medical centers to allow more personalized preoperative counseling than the population-based outcome statistics at present.

The Luna AI surgical intelligence platform of Intuitive Surgical, which involves machine learning analysis of the telemetry data of robotic surgery, which it analyzes and compares with benchmarking results, is the most commercially developed AI surgical intelligence platform as of today, offering surgical performance metrics and comparative benchmarking that can be used by programs to evaluate training progress and to find areas of performance improvement.

Category Wise Insights

By Product Type

Why Do Robotic Surgical Systems Lead the Market?

In 2025, robotic surgical systems represent the largest product type segment, accounting for approximately 52% of total market share. This dominance reflects the capital equipment nature of robotic surgical platforms — which represent multi-million dollar hospital investments generating concentrated revenue per unit transaction — combined with Intuitive Surgical's established and extensively installed da Vinci fleet that generates recurring revenue through annual service contracts, instrument and accessory consumable sales, and system upgrade programs that create sustained per-system revenue streams well beyond the initial capital sale. Intuitive Surgical's annual reports consistently demonstrate that the installed base of da Vinci systems generates an average procedure-linked revenue per system — through consumable instruments and accessories sold on a per-procedure basis — that contributes substantially to total company revenue alongside system sales, creating a business model in which the growing global installed base generates compounding recurring revenue.

The da Vinci Xi system — Intuitive Surgical's current flagship multiport platform — is priced at approximately USD 2 million per system with annual service contracts of USD 150,000–USD 200,000, while wristed EndoWrist instruments used during robotic prostatectomy procedures are priced at USD 600–USD 1,200 per instrument with limited use counts before mandatory replacement. The arrival of competing robotic systems at lower price points — CMR Surgical's Versius system targeting a more accessible capital cost and Medtronic's Hugo offering competitive terms — is creating downward pressure on robotic system pricing that is moderating revenue growth in the capital equipment segment while expanding the total addressable installation base as the lower price barrier enables adoption at community hospitals and emerging market centers previously unable to justify the full da Vinci cost commitment.

By Procedure Type

Why Does Radical Prostatectomy Dominate the Market?

Radical prostatectomy — the complete surgical removal of the prostate gland with its capsule, the seminal vesicles, and typically the pelvic lymph nodes in patients with adequate life expectancy and clinically localized prostate cancer — represents the largest procedure type segment at approximately 67% of total market share in 2025, reflecting radical prostatectomy's established position as one of the two primary curative-intent treatments for localized prostate cancer alongside external beam radiotherapy. The clinical decision between radical prostatectomy and radiotherapy for localized prostate cancer is influenced by patient age, tumor characteristics, comorbidities, patient preference, and institutional experience, with surgery generally favored in younger, healthier patients where the long-term cancer control benefit is most likely to translate into meaningful life extension, and where post-treatment urological management of any recurrence is facilitated by the absence of prior pelvic irradiation. The annual volume of radical prostatectomies.

By End-User

Why Do Hospitals Dominate the Market?

The largest end-user base is in hospitals, at around 74% representative of the market share in 2025, indicating the intensity of capital and complexity of robotic surgical platform implementation and maintenance, that is, dedicated operating room infrastructure, biomedical engineering support, sterile capable processing facilities to handle multi-component robotic instrumentation systems, and anesthesia and intensive care backup to facilitate large urological surgery, which has historically limited robotic prostatectomy to well-capitalized hospital operating settings. The largest volume urology programs in academic medical centers and large health systems are the initial adopters of robotic surgical devices, and the critical volume threshold of 150-250 robotic prostatectomies per year per system is needed to reach a break-even point on capital investment and keep surgeons proficient in robotic prostatectomy and thereby concentrate robotic prostatectomy in established volume centers. The hospital part is also characterized by the preponderance of large multi-specialty health systems - such as HCA Healthcare, CommonSpirit Health, Ascension Health, and similar integrated delivery networks in Europe - available to make the enterprise-level investment commitment of robotic surgery by purchasing more than one da Vinci system into their network of hospitals, with their negotiating scale offering them good instrument pricing deals with Intuitive Surgical.

By Application

Why Does Prostate Cancer Dominate the Market?

The largest share of the laparoscopic robotic assisted prostatectomy market is represented by the applications in prostate cancer treatment, constituting about 88% of the total market share in 2025, which is due to radical prostatectomy as the primary method of surgical treatment of prostate cancer and the fact that the robotic prostatectomy technology would be used almost exclusively in the treatment of the prostate cancer in the current clinical practice. The GLOBOCAN 2022 data providing a figure of 1.47 million new cases of prostate cancer cases in the world annually provides the epidemiologic basis of the volume of the market, with the rates of surgery treatment dependent on each country, the nature of the healthcare system, and the features of the population of patients but constituting a large part of the overall population of patients with prostate cancer treatment. Simple robotic prostatectomy: The application of simple robotic prostatectomy to benign prostate hyperplasia - a non-malignant enlargement of the prostate that leads to lower urinary tract symptoms in elderly men - is an emerging use of endoscopic robotic prostatectomy (Holep and robotic simple prostatectomy of large volume glands), with reported series showing the practicality and clinical utility of robotic simple prostatectomy to benign prostate hyperplasia in selected patients with very large prostate glands where endoscopic techniques have proven.

Report Scope

Regional Analysis

How Big is the North America Market Size?

The North America laparoscopic robotic assisted prostatectomy market size is estimated at USD 1.92 billion in 2025 and is projected to reach approximately USD 4.79 billion by 2035, with a CAGR of 9.6% from 2026 to 2035.

Why Did North America Dominate the Market in 2025?

In 2025, the United States market is in control of about 46% of the global market share, which is an indication of the fact that the United States of America is the largest robotic prostatectomy market in the world with over 85% of all radical prostatectomies operated using robotic methods according to published urological surgery literature, the highest density of installed da Vinci surgical systems; and the most comprehensive commercial infrastructure supporting robotic urological surgery including Intuitive Surgical broad field service and clinical training organization, supportive reimbursement climates in Robotic prostatectomy were developed in the United States, where the first robotic radical prostatectomy was done in the Henry Ford Hospital in Detroit in 2000, and had more than 20 years of clinical experience building, technique perfecting, and quality improvement program building that has developed robotic prostatectomy into a standard operation at hundreds of hospital programs across the United States with well-trained surgical teams and optimized ERAS pathways. The American Urological Association system of residency and fellowship training that has been established, including urology residency programs in large Academic Medical Centers that include robotic surgery simulation training and case experience as a regular part of urological surgical training.

Why is Europe a Strategically Important Market?

Estimates suggest that the European laparoscopic robotic assisted prostatectomy market will grow to about USD 1.09 billion in 2025 and will grow to about USD 2.58 billion by 2035 with a CAGR of 9.0. The market of Europe is of basic strategic significance, owing to the leading scale of robotic prostatectomy in Germany, which is Europe's largest robotic prostatectomy market with the best proportion of da Vinci system presence and excellent environments of adoption of robotic techniques in urology, the robotic surgery venture by the UK's National Health Service that has expanded the avenue of da Vinci system in NHS England via a national procurement framework, and the high rates of robotic prostatectomy adoption in France with its rising robotic surgery platform uptake and the UK with its The clinical guidelines of the European Association of Urology, the official evidence-based practice guideline of European urologists, expressly approve that robotic assisted laparoscopic prostatectomy is an established surgical practice in localized prostate cancer and therefore endorse the guideline level of clinical validation needed to support reimbursement and institutional investment in robotic surgery sites in the European healthcare systems. CMR Surgical's Versius system, which has its European base in the UK and Germany (headquartered in Cambridge, UK), is finding market penetration as a cheaper competitive option to the da Vinci in the European hospital procurement market, and Versius systems are now in operation at NHS trusts and private hospitals in Europe generating higher volumes of procedures and providing competitive pressure that is increasingly giving the economics of robotic surgery access in the European market.

Why is Asia Pacific the Fastest-Growing Market?

The fastest growing regional market in the future is Asia Pacific with the prospective CAGR between 2026 and 2035 of 13.4% driven by the accelerating number of robotic surgical platforms installed in major hospitals in Japan, South Korea, China, India, and Australia, the increasing rates of incidence of prostate cancer across the populations in Asia, which are historically lower than Western rates but rising with dietary westernization and aging demographics, and the rising demand of the patients in the Asian market to undergo surgery in a minimal invasive procedure and high-end Japan is the most commercialised Asian market in robotic prostatectomy with the presence of da Vinci systems in major university hospitals and cancer centres nationwide, the national health insurance system in Japan, approving robotic prostatectomy reimbursement, and urology specialist training programs including robotic prostatectomy.

Why is the Middle East & Africa Region an Emerging Market?

The LAMEA region is evidenced with the increasing market development as demonstrated by investment by the Gulf Cooperation Council in the world-class cancer treatment infrastructure of hospitals such as Cleveland Clinic Abu Dhabi, Hamad Medical Corporation of Qatar, and King Faisal Specialist Hospital of Saudi Arabia - hospitals that have developed robotic prostatectomy programs serving the local population as well as the medical tourism population - Brazil's highly developed oncology hospital infrastructure at cancer facilities such as Hospital AC Camargo and Hospital Sao Paulo Giga hospital groups using robotic surgery, and South Africa's privately The medical tourism industry of the Middle East, where Dubai Healthcare City and the medical district in Abu Dhabi are drawing in patients in large numbers with a specific interest in more technical robotic prostatectomy, imposes local pressure on the most technologically advanced equipment of the GCC region hospitals that are invested in the process of building the international center-of-excellence reputation of surgical services.

Top Players in the Market and Their Offerings

• Intuitive Surgical Inc.

• Medtronic plc (Hugo RAS System)

• CMR Surgical Ltd. (Versius System)

• Johnson & Johnson MedTech (Ottava System)

• Stryker Corporation

• Olympus Corporation

• Karl Storz SE & Co. KG

• Richard Wolf GmbH

• Becton Dickinson and Company

• Avatera Medical GmbH

• Asensus Surgical Inc. (Intelligent Surgical Unit)

• Others

Key Developments

The market has undergone significant developments as industry participants seek to expand competitive robotic surgery platform capabilities, advance ambulatory prostatectomy program development, and respond to the growing global demand for robotic assisted prostatectomy driven by rising prostate cancer incidence and patient preference for minimally invasive surgical approaches.

• In March 2024: Intuitive Surgical declared the commercial introduction of its da Vinci 5 surgical system—the fifth-generation da Vinci platform including a significantly enhanced computing architecture with 10,000 times more computing capability than its initial force feedback capabilities to enable surgeons with real-time information on resistance when operating the robots on tissue in the first phase of a commercially available clinical robotic surgery system and an inbuilt AI surgical performance analytics platform offering surgeons real-time procedure metrics and postoperative case review data.

• In December 2025: Medtronic stated that it received FDA 510(k) clearance of the Hugo RAS System for soft tissue robotic assisted laparoscopic prostatectomy in the United States—a regulatory breakthrough making Hugo the first commercially acceptable robotic surgery competitor to the da Vinci system in the U.S. market.

These strategic operations have enabled companies to improve and consolidate market positions, develop next-generation robotic platform capabilities such as force feedback and AI surgical intelligence, develop competitive alternatives to the traditional Intuitive Surgical domination, capitalize on the massive growth opportunity presented by the upward trend in prostate cancer incidence; show clinical superiority of robotic over open hysterectomy operations, and increase global patient expectations of minimally invasive surgical solutions to treat prostate cancer.

The Laparoscopic Robotic Assisted Prostatectomy Market is segmented as follows:

By Product Type

• Robotic Surgical Systems (Capital Equipment — da Vinci, Hugo, Versius, and Others)

• Laparoscopic Instruments & Accessories (Wristed Instruments, Trocars, Clip Appliers)

• Visualization Systems (3D HD Camera Systems, Fluorescence Imaging)

• Energy Devices (Monopolar, Bipolar, Ultrasonic)

• Other Product Types (Retractors, Sutures, Surgical Drapes)

By Procedure Type

• Radical Prostatectomy (Robotic Assisted Laparoscopic Radical Prostatectomy — RALP)

• Nerve-Sparing Prostatectomy (Unilateral and Bilateral Nerve-Sparing RALP)

• Extended Pelvic Lymph Node Dissection with Prostatectomy

• Simple Prostatectomy (for Benign Prostatic Hyperplasia)

• Other Procedure Types

By End-User

• Hospitals (Academic Medical Centers and Community Hospitals)

• Ambulatory Surgical Centers (ASCs)

• Specialty Urology Clinics

• Other End-Users

By Application

• Prostate Cancer (Localized and Locally Advanced)

• Benign Prostatic Hyperplasia (BPH)

• Other Applications

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America